Genmab Announced Sunday At ESMO, Updated Phase 2 Petosemtamab Plus Chemotherapy Data Showing 75% First-Line, 67% Second-Line Response Rates In Metastatic Colorectal Cancer

Loading news article.

Genmab Announced Sunday At ESMO, Updated Phase 2 Petosemtamab Plus Chemotherapy Data Showing 75% First-Line, 67% Second-Line Response Rates In Metastatic Colorectal Cancer | WAPE

Genmab Announced Sunday At ESMO, Updated Phase 2 Petosemtamab Plus Chemotherapy Data Showing 75% First-Line, 67% Second-Line Response Rates In Metastatic Colorectal Cancer

Article summary

Related companies

Comments —